Published online May 20, 2022. doi: 10.5662/wjm.v12.i3.107
Peer-review started: October 26, 2021
First decision: December 17, 2021
Revised: December 18, 2021
Accepted: March 16, 2021
Article in press: March 16, 2021
Published online: May 20, 2022
Two trials have been published to assess the effectiveness of lutetium in metastatic prostate cancer. The need to convert these effectiveness data into a pooled estimate represents a useful opportunity to test an innovative technique of individual patient reconstruction based on the analysis of Kaplan-Meier curves (shiny method).
The main motivation was to test the performance of the shiny method based on a real data-set.
Clarifying the effectiveness of lutetium in metastatic prostate cancer and confirm the reliability of the shiny method as a tool for reconstructing individual patient data.
The clinical trials that have thus far evaluated lutetium in metastatic prostate cancer have been identified by standard literature search. A pooled survival curve has been generated from these trials by using the shiny technique of individual patient data reconstruction.
Two clinical trials were identified. A pooled Kaplan-Meier survival curve was generated that synthesizes the current evidence on the effectiveness of this treatment in this disease condition.
A two-fold conclusion: First, lutetium is effective in metastatic prostate cancer; second, the Shiny technique can successfully be used to pool survival data from two trials without employing any meta-analytical method.
The shiny technique has been confirmed to be a useful new tool for analyzing survival data from multiple trials and therefore deserves to be further applied in the analysis of clinical evidence.